Hepatitis B and C viruses serology in patients with SLE

Abu‐Shakra, Mahmoud; Elsana, S.; Margalith, Miriam; Sikuler, Emanuel; Neumann, Lily; Buskila, Dan

doi:10.1177/096120339700600612

Cited by 48 publications

(22 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These autoantibodies were chosen for the study because they are common antibodies in systemic autoimmune diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) and systemic sclerosis (SSc). Due to its lymphotropism, HCV has been reported to be associated with a broad spectrum of autoimmune manifestations, including cryoglobulinaemia, Sicca syndrome, vasculitis and lymphoproliferative disorders [2][3][4][5][6][7][8], but there remains some controversy as to whether it plays a role in the pathogenesis of autoimmune diseases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection

Zhang

Hsu

Chen³

et al. 2002

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARY Hepatitis C virus (HCV) infection has been found to be strikingly associated with autoimmune phenomena. The aim of the present study was to investigate the presence of various autoantibodies in patients with HCV infection. Anti-neutrophil cytoplamic antibody (ANCA), anti-dihydrolipoamide dehydrogenase (anti-E3), rheumatoid factor (RF), anti-dihydrolipoamide acetyltransferase (anti-E2), anti-SS-A/Ro (60 kD), anti-SS-A/Ro (52 kD), anti-SS-B/La, anti-topoisomerase II (anti-topo II), anti-cardiolipin (aCL), anti-dsDNA, anti-ssDNA, anti-nuclear antibodies (ANA), anti-proteinase 3 (anti-Pr3) and anti-myeloperoxidase (anti-MPO) were determined in sera from 516 patients with HCV infection, 11 with primary biliary cirrhosis (PBC) and 44 healthy controls. Assays employed were indirect immunofluoresence, the particle latex agglutination test, enzyme-linked immunosorbent assay (ELISA) and immunoblotting. ANCA, anti-E3 antibody and RF were positive in 278/516 (55·6%), 276/516 (53·3%) and 288/516 (56%) patients with HCV infection, respectively. Positivity for ANA was present in 15·8%, anti-ssDNA in 15·6%, anti-dsDNA in 8·5%, aCL in 5%, anti-SS-B/La in 4·1%, anti-SS-A/Ro (60 kD) in 3·9%, anti-E2 in 3·3% and anti-SSA/Ro (52 kD) in 1·2%, anti-MPO in 4·8%, anti-Topo II and anti-actinin in 0%. All sera with ANCA showed c-ANCA patterns and contained anti-PR3 specificity. HCV patients with ANCA showed a higher prevalence of skin involvement, anaemia, abnormal liver function and α-Fetoprotein (α-FP). HCV patients with anti-E3 antibodies showed a higher prevalence of liver cirrhosis, arthritis, abnormal liver function and elevated α-FP levels. The prevalence of autoantibodies was not affected by treatment with interferon-alpha (IFN-α). In conclusion, autoantibodies are commonly found in patients with HCV infection. There is a high prevalence of anti-E3, ANCA and RF in these patients. Proteinase 3 and E3 are the major target antigens in HCV infection. HCV may be regarded as a possible causative factor in ANCA-related vasculitis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The association of HCV infection and autoimmunity has been reported [2][3][4][5][6][7]. Several studies have suggested that chronic HCV may act as a trigger for the development of autoimmune rheumatic diseases [2][3][4][5][6][7][8]. The role of HCV in these disorders has not been established.…”

Section: Introductionmentioning

confidence: 99%

Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection

Zhang

Hsu

Chen³

et al. 2002

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…In some epidemiological studies, the prevalence of HCV in patients with SLE was similar to those of anti-HCV antibodies found in the general population [8,52,53]. However, using polymerase chain reaction, other studies reported that the prevalence of HCV in patients with SLE was found to be higher than that in blood donors [8,51,54,55].…”

Section: Hcv Infection In Patients With Slementioning

confidence: 70%

Liver Complications Associated with Systemic Lupus Erythematosus

Shizuma

2015

Rheumatology (Sunnyvale)

View full text Add to dashboard Cite

Although liver dysfunction is not considered the main organ pathology or prognostic factor in patients with Systemic Lupus Erythematosus (SLE), it is not uncommon during the course of SLE. Liver complications in patients with SLE may be caused by lupus hepatitis (SLE-related hepatitis); autoimmune liver diseases, such as Autoimmune Hepatitis (AIH) and Primary Biliary Cirrhosis (PBC); viral hepatitis; and drug-induced liver injury. Here, liver complications in patients with SLE are reviewed.

show abstract

“…Previous reports regarding the prevalence of HBV infection in lupus patients from various countries are summarized in Table 1 (Permin et al 1982;Bonafede et al 1986;Chng et al 1993;Abu-Shakra et al 1997;Lu et al 1997;Ram et al 2008;Watanabe et al 2013). In previous studies by other groups, anti-HBs and anti-HBc were measured with a radioimmunoassay that was less sensitive than CLIA used in our study ).…”

Section: Prevalence Of Hbv Infection In Lupus Patientsmentioning

confidence: 71%

Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus

Watanabe

Ishii

Harigae

2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is one of the most common diseases, and approximately two billion people are infected with HBV in the world. Until recently, hepatitis B surface antigen (HBsAg)-negative patients, carrying hepatitis B surface antibody (anti-HBs) and/or hepatitis B core antibody (anti-HBc), have been considered to have achieved the resolution of HBV infection; however, among those patients, the reactivation of HBV has been increasingly reported after chemotherapy, hematopoietic stem cell transplantation, or immunosuppressive therapy. The reactivation of HBV can cause lethal hepatitis called de novo hepatitis B. Therefore, serological examination for HBV infection before starting immunosuppressive therapy is now recommended for all patients with rheumatic diseases. Systemic lupus erythematosus (SLE) is one of the autoimmune diseases characterized by the production of autoantibodies and usually requires immunosuppressive therapy. However, to date, a few reports are available regarding the prevalence and time course of HBV infection in patients with SLE under immunosuppressive therapy. In this review, we update the prevalence and time course of HBV infection in lupus patients using our data and previous papers available, with a special emphasis on occult HBV infection and a decrease of HBV-related antibodies (anti-HBs and anti-HBc) under immunosuppressive therapy. This review also highlights the screening and management of HBV infection currently recommended and the potential role of HBV infection in the pathogenesis of SLE. Throughout the present review, we recommend the pretreatment screening for HBV infection in patients with SLE as well as patients with other rheumatic diseases.

show abstract

Hepatitis B and C viruses serology in patients with SLE

Cited by 48 publications

References 6 publications

Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection

Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection

Liver Complications Associated with Systemic Lupus Erythematosus

Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus

Contact Info

Product

Resources

About